Escherichia coli sequence type 131: Epidemiology and challenges in treatment

Zubair A. Qureshi, Yohei Doi

研究成果: Review article査読

12 被引用数 (Scopus)

抄録

Escherichia coli ST131 has emerged as a global epidemic, multidrug-resistant clone of E. coli causing extra-intestinal infections. It is now highly prevalent among fluoroquinolone-resistant and CTX-M ESBL-producing E. coli isolates worldwide. Humans are likely the primary reservoir of ST131. Factors associated with its acquisition include residence in long-term care facilities and recent receipt of antimicrobial agents. E. coli ST131 causes a wide array of infections ranging from cystitis to life-threatening sepsis. Fluoroquinolones and trimethoprim-sulfamethoxazole are no longer adequate options for empiric therapy when E. coli ST131 is suspected from risk factors and local epidemiology. Expanded-spectrum cephalosporins, piperacillin- tazobactam and carbapenems are options to treat serious non-ESBL-producing E. coli ST131 infections, while carbapenems are indicated for ESBL-producing infections. There is a growing interest in reevaluating oral agents including fosfomycin and pivmecillinam for less serious infections such as uncomplicated cystitis.

本文言語English
ページ(範囲)597-609
ページ数13
ジャーナルExpert Review of Anti-Infective Therapy
12
5
DOI
出版ステータスPublished - 05-2014
外部発表はい

All Science Journal Classification (ASJC) codes

  • 微生物学
  • 微生物学(医療)
  • 感染症
  • ウイルス学

フィンガープリント

「Escherichia coli sequence type 131: Epidemiology and challenges in treatment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル